-
Crisaborole
Zita reAPI Indication Innovator Patent Expiry Date (The US) Crisaborole Atopic Dermatitis uye Eczema Pfizer -
Etelcacetide
Zita reAPI Indication Innovator Patent Expiry Date (The US) Etelcacetide Secondary hyperparathyroidism (HPT) Amgen -
Abemaciclib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Abemaciclib Kenza yemazamu, kurapwa kenza yeprostate Eli Lily Zvita.15,2029 -
Deucracitinib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Deucracitinib Anti plaque psoriasis Bristol-Myers Squibb Kambani Nov.07,2033 -
Apremilast
Zita reAPI Indication Innovator Patent Expiry Date (The US) Apremilast psoriatic arthritis Celgene -
Remdesivir
Zita reAPI Indication Innovator Patent Expiry Date (The US) Remdesivir Antivirus (Ebola, Covid-19) Gireadhi -
Paxlovid
Zita reAPI Indication Innovator Patent Expiry Date (The US) Paxlovid Covid 19 Pfizer -
Pomalidomide
Zita reAPI Indication Innovator Patent Expiry Date (The US) Pomalidomide Oncology mushonga Celgene -
Nirmatrelvir
Zita reAPI Indication Innovator Patent Expiry Date (The US) Nirmatrelvir 3C-Senge Protease (3CLPRO) Inhibitor uye SARS-Cov-2 Mpro Inhibitor -
Elrombopag
Zita reAPI Indication Innovator Patent Expiry Date (The US) Elrombopag ITP & Aplastic anemia Novartis & GSK Chivabvu. 20, 2023 -
Ruxolitinib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Ruxolitinib Myelofibrosis Novartis Chikunguru. 6, 2024 -
Crisaborole
Zita reAPI Indication Innovator Patent Expiry Date (The US) Crisaborole Atopic Dermatitis uye Eczema Pfizer Jun. 11, 2026